Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the ...
André Cerbe, CEO of Schlafender Hase, spoke with Pharmaceutical Technology® about the disruptions the pharma industry faced in 2025 and how digital workflows will be key for success in 2026. After a ...
Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions ...
AI emerged as a key differentiator in accelerating development timelines and enhancing clinical operations. Decentralized trial infrastructure and real-world data integration unlocked new operational ...
Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA / ACCESS Newswire / January 12, 2026 / Amphastar Pharmaceuticals, ...
GlobalData on MSN
FDA increases manufacturing flexibility for cell and gene therapies
Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.
Oral semaglutide was approved by the FDA in December 2025 as a once-daily pill (25 mg), intended to limit excess body weight ...
Upslope Capital Management, an investment management company, released its fourth-quarter 2025 investor letter. A copy of the ...
The government and private investors have agreed to deepen cooperation to fast-track local pharmaceutical production as ...
Sonia Lobo, an assistant professor in the department of humanities at NMAM Institute of Technology, Nitte, has been awarded a ...
Study Finds on MSN
Pharmaceutical Pollution Is Fueling A Superbug Crisis
Antibiotic factories release resistance genes at levels 100x higher than city sewage. Pharmaceutical pollution is fueling ...
Price target rises to $275 from Jefferies. Company partners with Lilly on $1B AI drug lab. Analysts see stock trading cheap.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback